| Metabolic footprints and molecular subtypes in breast cancer V Cappelletti, E Iorio, P Miodini, M Silvestri, M Dugo, MG Daidone Disease markers 2017, 2017 | 82 | 2017 |
| The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells C Reduzzi, M Vismara, L Gerratana, M Silvestri, F De Braud, ... Seminars in Cancer Biology 60, 344-350, 2020 | 40 | 2020 |
| Early modulation of circulating microRNAs levels in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy S Di Cosimo, V Appierto, S Pizzamiglio, M Silvestri, J Baselga, M Piccart, ... International journal of molecular sciences 21 (4), 1386, 2020 | 39 | 2020 |
| Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy E Ortolan, V Appierto, M Silvestri, R Miceli, S Veneroni, S Folli, G Pruneri, ... ESMO open 6 (2), 100086, 2021 | 36 | 2021 |
| Analysis of single circulating tumor cells in renal cell carcinoma reveals phenotypic heterogeneity and genomic alterations related to progression V Cappelletti, E Verzoni, R Ratta, M Vismara, M Silvestri, R Montone, ... International journal of molecular sciences 21 (4), 1475, 2020 | 33 | 2020 |
| A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer C Reduzzi, M Vismara, M Silvestri, L Celio, M Niger, G Peverelli, ... International journal of cancer 146 (12), 3495-3503, 2020 | 22 | 2020 |
| Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk E De Mattia, M Silvestri, J Polesel, F Ecca, S Mezzalira, L Scarabel, ... Biomedicine & Pharmacotherapy 154, 113644, 2022 | 21 | 2022 |
| Single-cell phenotypic and molecular characterization of circulating tumor cells isolated from cryopreserved peripheral blood mononuclear cells of patients with lung cancer and … M Vismara, C Reduzzi, M Silvestri, F Murianni, G Lo Russo, O Fortunato, ... Clinical Chemistry 68 (5), 691-701, 2022 | 16 | 2022 |
| Targeted-gene sequencing to catch triple negative breast cancer heterogeneity before and after neoadjuvant chemotherapy S Di Cosimo, V Appierto, M Silvestri, G Pruneri, A Vingiani, F Perrone, ... Cancers 11 (11), 1753, 2019 | 16 | 2019 |
| Low expression of Claudin-7 as potential predictor of distant metastases in high-grade serous ovarian carcinoma patients C Romani, V Zizioli, M Silvestri, L Ardighieri, M Bugatti, M Corsini, ... Frontiers in oncology 10, 1287, 2020 | 12 | 2020 |
| Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer M Silvestri, M Dugo, M Vismara, L De Cecco, D Lanzoni, A Vingiani, ... Scientific Reports 12 (1), 1470, 2022 | 11 | 2022 |
| Detection of genomically aberrant cells within circulating tumor microemboli (CTMs) isolated from early-stage breast cancer patients M Silvestri, C Reduzzi, G Feliciello, M Vismara, T Schamberger, C Köstler, ... Cancers 13 (6), 1409, 2021 | 11 | 2021 |
| Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma M Silvestri, T Nghia Vu, F Nichetti, M Niger, S Di Cosimo, F De Braud, ... Cancer Medicine 12 (8), 10156-10168, 2023 | 6 | 2023 |
| The claudin-low subtype of high-grade serous ovarian carcinoma exhibits stem cell features C Romani, D Capoferri, E Grillo, M Silvestri, M Corsini, L Zanotti, ... Cancers 13 (4), 906, 2021 | 6 | 2021 |
| Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. ESMO Open. 2021; 6 (2): 100086 E Ortolan, V Appierto, M Silvestri, R Miceli, S Veneroni, S Folli | 5 | 2021 |
| Can we define breast cancer HER2 status by liquid biopsy? S Di Cosimo, C De Marco, M Silvestri, A Busico, A Vingiani, G Pruneri, ... International Review of Cell and Molecular Biology 381, 23-56, 2023 | 3 | 2023 |
| End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO S Di Cosimo, CM Ciniselli, S Pizzamiglio, V Cappelletti, M Silvestri, ... Frontiers in Oncology 12, 1028825, 2023 | 3 | 2023 |
| CK+/CD45+ (dual-positive) circulating cells are associated with prognosis in patients with advanced breast cancer. C Reduzzi, L Gerratana, Y Zhang, P D'Amico, AN Shah, AA Davis, ... Journal of Clinical Oncology 40 (16_suppl), 1093-1093, 2022 | 3 | 2022 |
| Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA E La Rocca, MC De Santis, M Silvestri, E Ortolan, M Valenti, S Folli, ... Journal of Cancer Research and Clinical Oncology 148 (6), 1543-1550, 2022 | 3 | 2022 |
| Circulating tumor DNA and disease recurrence in early stage breast cancer: From a case-control study to a prospective longitudinal trial S Di Cosimo, V Appierto, E Ortolan, F Dell’Angelo, M Silvestri, G Bianchi, ... Annals of Oncology 30, iii28-iii29, 2019 | 3 | 2019 |
Maria grazia DaidoneFondazione IRCCS Istituto Nazionale dei TumoriVerified email at istitutotumori.mi.it
